%PDF-1.4
%
28 0 obj
<>
endobj
25 0 obj
<>
endobj
73 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-09T13:06:51Z
2024-03-29T06:06:27-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T06:06:27-07:00
application/pdf
Heather
2001-336.aug02
uuid:1b618a19-1dd2-11b2-0a00-ab0827edca00
uuid:1b618a1b-1dd2-11b2-0a00-380000000000
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
<>
endobj
29 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
87 0 obj
[91 0 R]
endobj
88 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 714.5293 Tm
[(18.)-875.1 (Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF)79.7 (, Kohler)]TJ
0 Tc 2.175 -1.25 Td
[(JA. )54.9 (Adverse experience with methotrexate during 176 weeks of a)]TJ
0 -1.25 TD
(longterm prospective trial in patients with rheumatoid arthritis. J)Tj
T*
(Rheumatol 1990;17:1628-35.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Furst DE, Koehnke R, Burmeister LF)79.7 (, Kohler J, Car)17.7 (gill I.)]TJ
0 Tc 2.175 -1.25 Td
[(Increasing methotrexate ef)17.8 (fect with increasing dose in the treatment)]TJ
T*
(of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-20.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Roenigk HH Jr)39.7 (, )54.8 (Auerbach R, Maibach HI, )17.7 (W)79.7 (einstein GD.)]TJ
2.175 -1.25 Td
[(Methotrexate in psoriasis: revised guidelines. J )54.8 (Am )54.8 (Acad Dermatol)]TJ
0 Tc 0 Tw T*
(1988;19:145-56.)Tj
0.0249 Tw -2.175 -1.25 Td
[(21.)-875 (Emery P)110.8 (, Salmon M. Early rheumatoid arthritis: time to aim for)]TJ
2.175 -1.25 Td
[(remission? )54.9 (Ann Rheum Dis 1995;54:944-7.)]TJ
-2.175 -1.25 Td
[(22.)-875 (Pincus )17.8 (T)74 (. Rheumatoid arthritis: disappointing long-term outcomes)]TJ
2.175 -1.25 Td
(despite successful short-term clinical trials. J Clin Epidemiol)Tj
0 Tw T*
(1988;41:1037-41.)Tj
0.0249 Tw 30.825 17.5 Td
[(23.)-875 (Kremer JM. Safety)64.9 (, ef)17.8 (ficacy)64.9 (, and mortality in a long-term cohort of)]TJ
2.175 -1.25 Td
(patients with rheumatoid arthritis taking methotrexate: followup)Tj
T*
[(after a mean of 13.3 years. )54.9 (Arthritis Rheum 1997;40:984-5.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (W)79.7 (alker )54.8 (AM, Funch D, Dreyer NA, et al. Determinants of serious)]TJ
0 Tc 2.175 -1.25 Td
(liver disease among patients receiving low-dose methotrexate for)Tj
T*
[(rheumatoid arthritis. )54.9 (Arthritis Rheum 1993;36:329-35.)]TJ
-2.175 -1.25 Td
[(25.)-875 (Fries JF)79.8 (, Ramey RD, Singh G. Suggested guidelines for monitoring)]TJ
2.175 -1.25 Td
(liver toxicity in rheumatoid arthritis patients treated with)Tj
T*
[(methotrexate: comment on article by Kremer et al [letter]. )54.9 (Arthritis)]TJ
T*
(Rheum 1994;37:1829-30.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Newman ED, Harrington )17.7 (TM, Perruquet JL, Davis DE, )17.7 (T)69.7 (orretti D.)]TJ
2.175 -1.25 Td
[(Creating a care-ef)17.7 (fective cost-ef)17.7 (fective strategy for methotrexate)]TJ
0 Tc T*
(liver toxicity monitoring in rheumatoid arthritis: comment on)Tj
T*
[(article by Kremer et al [letter]. )54.8 (Arthritis Rheum 1995;38:297.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Y)92 (azici, et al: Editorial)]TJ
0 Tw 60.9375 -0.0313 Td
(1589)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 57.75 407.5 -10.83 re
f*
0.5 w
102.25 57.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
64 0 obj
<>
endobj
78 0 obj
<>
endobj
32 0 obj
<>
endobj
33 0 obj
<>
endobj
35 0 obj
<>
endobj
39 0 obj
<>stream
HV pTU=!YI|1I͆ "tFRLADjBG0H aMJdQ(Y@B! N Ѫ闓;/ PP0^&$P;2PWSJkUR=_?ma,mڀcsK: YSQ(zH3UpO
*j> s**/2/. 9srTe`AUd|(M@eYӖ=ӯjMZ0^58I|$J$i2q=4
ip)A+Z>.m,54;1UQXec83G
/G})?
+/`!v N1v&
Q:x'baxmpc0#
ayV3pTכN0/'ڄ98CD.#hĐO ܱKD|k.wuD6<w
Vbi1UWd>8XW$5={>fgΡwpOh)"Dwϒ7⬌qҐ9%CV5ohu峊9֧,ϲ3q)sfwX±c3my<(NϿkЌ{OQ"#V$s
76]-DX,jXMħ+/}r\$qyR~+/kg%RIQ\A5_nӢiZVmw3/4145T:b9h+ݪYFvp%#0ؑvupMt؛f빞n6ޥC8~ϸ uN}NQ>3/OLS4Q.*a+8V7F]qSb{5%;H]f3#{P)k2|G/ҔaV{R*JҏëR(eZ٤lV*T)=r_VsԱjW=AkEZ6K{Yjh
Nva:
g5rgߴ_~v#g=>GqX"S|uIk!ެ(ǷNj#B$(u^ú@-:ta)=GpYc~LSy{z;3#Ov3~һvII۩bGj&2TE
dz~Lj1bۖ _(N}LvгWOCO w5tH7I|\3u9^ia;toBEn
5WW